Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis

Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory AL Amyloidosis#Immix #Biopharma #Receives #FDA #Regenerative #Medicine #Advanced #Therapy #RMAT #Designation #NXC201 #stericallyoptimized #CART #relapsedrefractory #Amyloidosis